What You Need to Know: COVID-19 Vaccine Allocation

The latest information on COVID-19 vaccines allocation and how the CF Foundation is advocating in your state.

8 min read
In this article
Summary
  • We believe people with CF need a vaccine distribution strategy that is aggressive, predictable, and adheres to science and medicine.
  • Throughout this pandemic, we have engaged with federal and state decision-makers about the dangers of respiratory infections for individuals with cystic fibrosis and the needs of the CF community during this time.

The Cystic Fibrosis Foundation recognizes the urgency and the importance of ensuring people living with cystic fibrosis have priority access to the COVID-19 vaccines. Throughout this pandemic, the Foundation has engaged with federal and state decision-makers about the dangers of respiratory infections for individuals with cystic fibrosis and the needs of the CF community.

Currently, three vaccines have been proven to be safe and effective and received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), one of which recently received full approval:

  • People ages 16 and older may receive the Pfizer-BioNTech vaccine, now known as Comiarty, which received full FDA approval on Aug. 23, 2021.
  • People ages 12 to 15 years may also receive the Pfizer-BioNTech vaccine, which received EUA from the FDA on May 11, 2021.
  • People ages 18 and older may receive the vaccine manufactured by Moderna and Jansen, which received EUAs on Dec. 18, 2020 and Feb. 27, 2021, respectively.
  • People whose immune systems are compromised, such as those who have had a solid organ transplant, may receive all available vaccines. However, the EUAs for the Pfizer-BioNTech and Moderna vaccines were amended by the FDA on Aug. 12, 2021, to be provided as a third dose.

The CF Foundation continues to monitor federal and state-level activities around COVID-19 vaccines to ensure access for people living with CF. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) makes recommendations about vaccine use in the United States, including recommendations about who should receive priority access to COVID-19 vaccines. These recommendations prioritized access to COVID-19 vaccines for people with high-risk medical conditions before the general public, including people with cystic fibrosis.

However, the ACIP recommendations are only one piece of vaccine allocation decisions. States, localities, and health care institutions all have a role in determining when people will have access to vaccines. Vaccine supplies as well as logistical issues and resource constraints at the state and local level will also affect when someone with CF will be able to receive a vaccine.

Vaccine allocation decisions are made locally

While states are encouraged to follow the recommendations from ACIP, final decisions on how vaccines are allocated and distributed are based on a combination of decisions made by federal, state, and local decision-makers, as well as health care institutions. As a result, there are significant differences based on where you live.

For the latest information on the vaccine rollout in your state visit the National Academy for State Health Policy (NASHP) resource that outlines state vaccine allocation plans.

The Foundation believes people with CF need a vaccine distribution strategy that is aggressive, predictable, and adheres to science and medicine. Read our recent statement here.

Our Advocacy Efforts

The CF Foundation continues to advocate both at the federal and state level to support vaccine access for people living with cystic fibrosis.

Federal Activity

  • September 23, 2021: CF Foundation letter to the ACIP asking for clarity on eligibility for Comirnaty booster doses and assurance that people with cystic fibrosis will be included in the definition of individuals at high-risk for severe COVID-19 disease.
  • September 21, 2021: CF Foundation letter to the FDA urging the agency to include people with cystic fibrosis in the definition of those at high-risk for severe COVID-19 disease when considering booster shot eligibility.
  • April 15, 2021: CF Foundation joins The Global Registry Harmonization Group in writing a letter to the editor of the Journal of Cystic Fibrosis supporting COVID-19 vaccine prioritization for people with cystic fibrosis and calling for distribution strategies that are aggressive, predictable, and adhere to science and medicine.
  • March 17, 2021: CF Foundation joins the International Society for Heart and Lung Transplantation and the Cystic Fibrosis Lung Transplant Consortium in responding to the CDC's Interim Public Health Recommendations for Fully Vaccinated People.
  • March 12, 2021: Statement for the record for the U.S. House of Representatives Committee on Energy and Commerce hearing on COVID-19 vaccine allocation and access.
  • March 1, 2021: Comments to ACIP on COVID-19 vaccine allocation urging the committee to ensure that allocation recommendations to states clearly reflect the need for early vaccine access for high-risk rare disease populations, including people living with CF.
  • February 28, 2021: Public testimony on COVID-19 vaccine allocation during the ACIP February meeting.
  • February 17, 2021: Ad hoc coalition letter to the CDC urging the agency to provide additional allocation guidance to states to ensure people living with rare diseases are able to access COVID-19 vaccinations at the appropriate time.
  • January 27, 2021: Comments to ACIP on COVID-19 vaccine allocation ahead of ACIP's January meeting.
  • January 21, 2021: Letter to President Joseph R. Biden, Jr. emphasizing the urgency for prioritized access to COVID-19 vaccines for people with CF.
  • January 4, 2021: Comments on U.S. Department of Health and Human Services' (HHS) interim rule regarding COVID-19 vaccine coverage, Medicaid maintenance of effort, and Section 1332 waiver process during the public health emergency.
  • December 18, 2020: Comments to ACIP on COVID-19 vaccine allocation, urging ACIP to not deprioritize rare disease populations for whom there is less evidence on the risks of COVID-19 infection and allow clinician discretion in identifying individuals who need prioritized vaccine access.
  • December 15, 2020: Comments to ACIP on COVID-19 vaccine allocation and the risks of COVID-19 infection for people with CF.
  • December 7, 2020: Letter to President-elect Biden outlining important policy issues for the CF community, including prioritized access to COVID-19 vaccines.
  • October 30, 2020: Comments to ACIP on COVID-19 vaccine allocation.
  • October 26, 2020: Public testimony on COVID-19 vaccine allocation during the ACIP October meeting.
  • September 4, 2020: Comments to the National Academies of Sciences, Engineering, and Medicine on their draft allocation framework for a COVID-19 vaccination.
  • August 26, 2020: Comments to ACIP on COVID-19 vaccine allocation.

State Activity

The Foundation has sent individualized letters to state health officials asking for prioritized access to COVID-19 vaccines for people with cystic fibrosis. Read the letter(s) to your state below.

Additional Resources

  • Learn more about how a vaccine is evaluated for use by the FDA.
  • The CF Foundation issued a statement on January 7, 2021 that strongly encouraged people with cystic fibrosis to talk with their CF care team about getting vaccinated. Read the statement.
  • On January 14, 2021, the CF Foundation hosted a Community Town Hall on COVID-19 vaccines. You can watch the recording in English or Spanish.
  • On February 28, 2021, CF Foundation leadership provided testimony at the ACIP monthly public meeting.
  • On March 1, 2021, the CF Foundation issued a statement reaffirming support for COVID-19 vaccinations for people with cystic fibrosis. Read the statement.
Share this article
Topics
Coronavirus (COVID-19) | Infections | Our Advocacy Work
Was this information helpful?
Have questions? We’re here to help. Call us at 1-800-FIGHT CF

(1-800-344-4823)
Mon - Thu, 9 am - 7 pm ET
Fri, 9 am - 3 pm ET

 

More Ways To Get Help